News

Is Ultra Clean Holdings (UCTT) Well Positioned to Increase Its Market Share Over the Long Term?
Frontier Capital Management, an investment management company, released its “Frontier Small Cap Growth Fund” first quarter ...
Here’s Why Penn Davis McFarland Sold Fortrea Holdings (FTRE) in Q1
Penn Davis McFarland, an investment management company, released its first quarter 2025 investor letter. A copy of the letter ...
Marsh & McLennan Companies (MMC) Shares Fell in Q2. Here’s Why
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” second ...
Shift in Consumer Spending Challenged Target (TGT) in Q2
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” second ...
Clearbridge Large Cap Growth Strategy Sold Adobe (ADBE) Due to Concerns Over Market Penetration and Competition
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” second ...
Clearbridge Large Cap Growth Strategy Added Servicenow (NOW) to Elevate Select Growth Exposure
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” second ...
Clearbridge Large Cap Growth Strategy Sold Its Stake in ICON Public Limited Company (ICLR)
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” second ...
Apple Inc. (AAPL): “What Do We Pay For Apple?” Wonders Jim Cramer
Apple Inc. (NASDAQ:AAPL) has become a regular feature of Cramer’s morning show over the past couple of months. The firm’s ...
Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31
Dynavax Technologies Corporation (NASDAQ:DVAX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.
H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 1, ...
Piper Sandler Maintains a Buy Rating on Cytokinetics (CYTK) With a $107 PT
Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.